sofidexFor patientsAre you a clinician? Clinical site
Ask Sofi
Listen
Patient SupportEmergencies & Reporting
Log inSign up

Meds & supplements  ›  Nirsevimab

Medicine · Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody

Nirsevimab

BEYFORTUS is indicated for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in: Neonates and infants born during or entering their first RSV season.

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗

Drug facts

Used for
  • Neonates and infants born during or entering their first RSV season.
  • Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.
Do not take if
BEYFORTUS is contraindicated in infants and children with a history of serious hypersensitivity reactions, including anaphylaxis, to nirsevimab-alip or to any of the excipients.

What it is used for

BEYFORTUS is indicated for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in:

  • Neonates and infants born during or entering their first RSV season.
  • Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

Who should not take it

BEYFORTUS is contraindicated in infants and children with a history of serious hypersensitivity reactions, including anaphylaxis, to nirsevimab-alip or to any of the excipients.

Storing it

Storage and Handling

Store refrigerated between 36°F to 46°F (2°C to 8°C). BEYFORTUS may be kept at room temperature 68°F to 77°F (20°C to 25°C) for a maximum of 48 hours. After removal from the refrigerator, BEYFORTUS must be used within 48 hours or discarded.

Store BEYFORTUS in original carton to protect from light until time of use.

Do not freeze. Do not shake. Do not expose to heat.

Cite this page

NLM

sofidex [Internet]. Daloreum; c2026. Nirsevimab; [reviewed 2026 Aug 3; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/nirsevimab

APA 7th

sofidex. (2026, August 3). Nirsevimab. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/nirsevimab

AMA 11th

Nirsevimab. sofidex. Reviewed August 3, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/nirsevimab

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.